Global Innovative Platforms Inc. Reports First Revenue of $30,000 and Improved Net Loss

Global Innovative Platforms Inc. reported its financial results for the three months ending December 31, 2025, revealing a revenue of $30,000, marking the company's first revenue recognition since its inception. This revenue was generated from a licensing agreement involving its proprietary VOCAM Plus diagnostic technology for detecting heartworm disease in dogs. In comparison, the company had no revenue during the same period in 2024. Despite this initial revenue, the company incurred a net loss of $49,429, a significant improvement from the loss of $120,467 reported in the prior year, reflecting a reduction in total expenses from $120,467 to $79,429.

The company's financial position showed notable changes, with total assets increasing to $224,951 as of December 31, 2025, up from $199,275 at the end of September 2025. This increase was primarily due to the capitalization of product development costs and the acquisition of property, plant, and equipment. However, total liabilities also rose sharply to $65,784 from $11,609, largely due to an increase in deferred revenue and accrued expenses. Stockholders' equity decreased to $159,567, down from $187,666, primarily due to the net loss incurred during the quarter.

Operationally, Global Innovative Platforms has made strides in its product development and market engagement. The company reported a decrease in research and development expenses to $10,681 from $34,250 year-over-year, indicating a more efficient allocation of resources. General and administrative expenses also fell to $68,748 from $86,217, reflecting a shift in focus towards operational activities rather than due diligence. The company’s employee headcount and customer base remain limited, with the current customer count being one, which is expected to grow as the company expands its market presence.

Looking ahead, Global Innovative Platforms faces significant challenges in securing additional funding to support its ongoing operations and product development. The company has expressed a need for substantial capital to continue its research and development efforts, particularly as it aims to commercialize its diagnostic technologies. The management has indicated that future financing will likely come from equity offerings or debt financing, but there is no assurance that such funding will be available on favorable terms. The company’s ability to continue as a going concern remains uncertain, as highlighted in its financial statements, which emphasize the need for additional capital to sustain operations and achieve profitability.